Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | PDE1A | P54750 | 7/20 | 0.63 |
| ▸ | PDE1B | Q01064 | 7/20 | 0.63 |
| ▸ | PDE1C | Q14123 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5603367 | 0.85 | PDE5A (0.58) | PDE5AKDM4EPDE1APDE1BPDE1C | |
| SCHEMBL5602775 | 0.83 | PDE5A (0.62) | PDE5AKDM4EPDE1APDE1BPDE1C | |
| SCHEMBL465934 | 0.80 | SMN1; SMN2 (0.51) | PDE5AKDM4E | |
| SCHEMBL3511778 | 0.78 | SMN1; SMN2 (0.50) | PDE5AKDM4E | |
| SCHEMBL17674539 | 0.78 | SMN1; SMN2 (0.50) | PDE5AKDM4E | |
| SCHEMBL12468610 | 0.78 | SMN1; SMN2 (0.50) | PDE5AKDM4EPDE1APDE1BPDE1C | |
| SCHEMBL353851 | 0.78 | SMN1; SMN2 (0.73) | PDE5AKDM4EPDE1APDE1BPDE1C | |
| SCHEMBL5599800 | 0.78 | SMN1; SMN2 (0.58) | PDE5AKDM4EPDE1APDE1BPDE1C | |
| SCHEMBL3612370 | 0.77 | SMN1; SMN2 (0.49) | PDE5AKDM4E | |
| SCHEMBL3597144 | 0.77 | SMN1; SMN2 (0.57) | PDE5AKDM4EPDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007017728-A2 | NOVEL HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-02-15 | — | — | WO | claimed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
| WO-2007017728-A2 | NOVEL HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | PDE5A 258/4885KDM4E 3755/4885PDE1A 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.